Takala A, Jousela I, Olkkola K T, Jansson S E, Leirisalo-Repo M, Takkunen O, Repo H
Department of Anaesthesia, Helsinki University Central Hospital, Anestesiaosasto, PO Box 260, FIN-00029 HYKS, Finland.
Clin Sci (Lond). 1999 Mar;96(3):287-95.
Criteria of the systemic inflammatory response syndrome (SIRS) are known to include patients without systemic inflammation. Our aim was to explore additional markers of inflammation that would distinguish SIRS patients with systemic inflammation from patients without inflammation. The study included 100 acutely ill patients with SIRS. Peripheral blood neutrophil and monocyte CD11b expression, serum interleukin-6, interleukin-1beta, tumour necrosis factor-alpha and C-reactive protein were determined, and severity of inflammation was evaluated by systemic inflammation composite score based on CD11b expression, C-reactive protein and cytokine levels. Levels of CD11b expression, C-reactive protein and interleukin-6 were higher in sepsis patients than in SIRS patients who met two criteria (SIRS2 group) or three criteria of SIRS (SIRS3 group). The systemic inflammation composite score of SIRS2 patients (median 1.5; range 0-8, n=56) was lower than that of SIRS3 patients (3.5; range 0-9, n=14, P=0.013) and that of sepsis patients (5.0; range 3-10, n=19, P<0.001). The systemic inflammation composite score was 0 in 13/94 patients. In 81 patients in whom systemic inflammation composite scores exceeded 1, interleukin-6 was increased in 64 (79.0%), C-reactive protein in 59 (72.8%) and CD11b in 50 (61.7%). None of these markers, when used alone, identified all patients but at least one marker was positive in each patient. Quantifying phagocyte CD11b expression and serum interleukin-6 and C-reactive protein concurrently provides a means to discriminate SIRS patients with systemic inflammation from patients without systemic inflammation.
已知全身炎症反应综合征(SIRS)的标准包括无全身炎症的患者。我们的目的是探索额外的炎症标志物,以区分有全身炎症的SIRS患者和无炎症的患者。该研究纳入了100例急性病SIRS患者。测定外周血中性粒细胞和单核细胞CD11b表达、血清白细胞介素-6、白细胞介素-1β、肿瘤坏死因子-α和C反应蛋白,并根据CD11b表达、C反应蛋白和细胞因子水平通过全身炎症综合评分评估炎症严重程度。脓毒症患者的CD11b表达、C反应蛋白和白细胞介素-6水平高于符合两条标准的SIRS患者(SIRS2组)或符合三条SIRS标准的患者(SIRS3组)。SIRS2患者(中位数1.5;范围0-8,n=56)的全身炎症综合评分低于SIRS3患者(3.5;范围0-9,n=14,P=0.013)和脓毒症患者(5.0;范围3-10,n=19,P<0.001)。94例患者中有13例的全身炎症综合评分为0。在全身炎症综合评分超过1的81例患者中,64例(79.0%)白细胞介素-6升高,59例(72.8%)C反应蛋白升高,50例(61.7%)CD11b升高。这些标志物单独使用时均不能识别所有患者,但每个患者至少有一个标志物呈阳性。同时定量吞噬细胞CD11b表达、血清白细胞介素-6和C反应蛋白为区分有全身炎症的SIRS患者和无全身炎症的患者提供了一种方法。